clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
de Luis DA et al. | Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. | 2001 | Diabetes Res. Clin. Pract. | pmid:11182211 |
Nightingale CH | A survey of the quality of generic clarithromycin products manufactured in Slovenia and Israel. | 2000 May-Jun | Adv Ther | pmid:11183454 |
Sato K et al. | Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. | 2000 | Int. J. Antimicrob. Agents | pmid:11185410 |
Taylor DE | Pathophysiology of antibiotic resistance: clarithromycin. | 2000 | Can. J. Gastroenterol. | pmid:11188799 |
Lahaie RG and Gaudreau C | Helicobacter pylori antibiotic resistance: trends over time. | 2000 | Can. J. Gastroenterol. | pmid:11188800 |
Adler JL et al. | Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. | 2000 | Clin Ther | pmid:11192133 |
Murray JJ et al. | Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. | 2000 | Clin Ther | pmid:11192134 |
Matsuo K et al. | [Pulmonary Nocardia otitidiscaviarum infection in an immunocompetent host]. | 2000 | Nihon Kokyuki Gakkai Zasshi | pmid:11193319 |
Katelaris PH | Helicobacter pylori: changing patterns of ulcer disease and antibiotic resistance. | 2000 | Med. J. Aust. | pmid:11194729 |
Mollison LC et al. | Antibiotic resistance in Helicobacter pylori. | 2000 | Med. J. Aust. | pmid:11194734 |
Badyal DK and Garg SK | Effect of clarithromycin on the pharmacokinetics of carbamazepine in rhesus monkeys. | 2000 | Methods Find Exp Clin Pharmacol | pmid:11196346 |
Kaipiainen-Seppänen O and Hyvärinen L | Adverse reactions to rifabutin. | 2001 | J. Rheumatol. | pmid:11196537 |
Nomura H et al. | A short-term eradication therapy for Helicobacter pylori acute gastritis. | 2000 | J. Gastroenterol. Hepatol. | pmid:11197046 |
Lee AJ and Maddix DS | Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. | 2001 | Ann Pharmacother | pmid:11197581 |
Koizumi T et al. | [Pulmonary Mycobacterium gordonae infection treated with clarithromycin]. | 2000 | Kekkaku | pmid:11201139 |
Felley CP et al. | Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. | 2001 | Eur J Gastroenterol Hepatol | pmid:11204805 |
Bortolotti M et al. | Effect of clarithromycin on esophageal motility. | 2000 | Dis. Esophagus | pmid:11206638 |
Wong BC et al. | One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207516 |
Fakheri H et al. | Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207517 |
Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
Iakovlev VP et al. | [Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections]. | 2000 | Antibiot. Khimioter. | pmid:11210297 |
Sazykin IuO et al. | [Clarithromycin and tumor chemotherapy]. | 2000 | Antibiot. Khimioter. | pmid:11210301 |
Pilotto A et al. | Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. | 2000 | Dig Liver Dis | pmid:11215555 |
Kato M et al. | [Recent guidelines for the management of Helicobacter pylori infection]. | 2001 | Nippon Rinsho | pmid:11218393 |
Inoue K et al. | [Antimicrobial resistant test of H. pylori]. | 2001 | Nippon Rinsho | pmid:11218400 |
Murakami K et al. | [Selection of antibiotics and planning of eradication for H. pylori infection]. | 2001 | Nippon Rinsho | pmid:11218403 |
Tanabe H et al. | [Usefulness of new triple therapy containing PPI]. | 2001 | Nippon Rinsho | pmid:11218404 |
Ohkusa T and Watanabe M | [A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment]. | 2001 | Nippon Rinsho | pmid:11218406 |
Maeda S and Yoshida H | [Mechanism of drug resistance in Helicobacter pylori]. | 2001 | Nippon Rinsho | pmid:11218414 |
Pijlman AH et al. | [Acute delirium, probably precipitated by clarithromycin]. | 2001 | Ned Tijdschr Geneeskd | pmid:11219151 |
Anzueto A et al. | Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. | 2001 | Clin Ther | pmid:11219481 |
Gotfried MH et al. | Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. | 2001 | Clin Ther | pmid:11219483 |
Malik R et al. | Treatment of canine leproid granuloma syndrome: preliminary findings in seven dogs. | 2001 | Aust. Vet. J. | pmid:11221566 |
de Dios GarcÃa-DÃaz J et al. | [Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of erythromycin versus clarithromycin]. | 2001 | Med Clin (Barc) | pmid:11222159 |
Wilcox MH | Clarithromycin and risk of Clostridium difficile-associated diarrhoea. | 2001 | J. Antimicrob. Chemother. | pmid:11222572 |
Miki H et al. | Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication. | 2001 | J. Gastroenterol. | pmid:11227668 |
Kim HS et al. | Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. | 2001 | J. Gastroenterol. | pmid:11227677 |
Kato K et al. | A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication. | 2001 | Gastrointest. Endosc. | pmid:11231401 |
Maconi G et al. | Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 | Am. J. Gastroenterol. | pmid:11232676 |
Ozluer SM and De'Ambrosis BJ | Mycobacterium abscessus wound infection. | 2001 | Australas. J. Dermatol. | pmid:11233716 |
Ishigo S et al. | [The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture]. | 2000 | Jpn J Antibiot | pmid:11234221 |
Cangelosi GA et al. | Phenotypic consequences of red-white colony type variation in Mycobacterium avium. | 2001 | Microbiology (Reading, Engl.) | pmid:11238960 |
Furuta T et al. | Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. | 2001 | Clin. Pharmacol. Ther. | pmid:11240980 |
Yazawa N et al. | The successful treatment of prurigo pigmentosa with macrolide antibiotics. | 2001 | Dermatology (Basel) | pmid:11244235 |
Leung WK and Graham DY | Clarithromycin for Helicobacter pylori infection. | 2000 | Expert Opin Pharmacother | pmid:11249534 |
Amábile-Cuevas CF et al. | Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. | 2001 | Clin. Infect. Dis. | pmid:11249826 |
Schentag JJ et al. | What have we learned from pharmacokinetic and pharmacodynamic theories? | 2001 | Clin. Infect. Dis. | pmid:11249828 |
Krasemann C et al. | Evaluation of the clinical microbiology profile of moxifloxacin. | 2001 | Clin. Infect. Dis. | pmid:11249830 |
Vergassola R et al. | [Chlamydia pneumoniae and myocardial infarction (CLINF). Preliminary randomized controlled study with clarithromycin. CLAINF protocol]. | 2000 | Minerva Cardioangiol | pmid:11253326 |
Bindayna KM | Antibiotic susceptibilities of Helicobacter pylori. | 2001 | Saudi Med J | pmid:11255612 |